The claim is largely true for drug development, but not for routine procedures. Those are expensive for unrelated, and largely pathological, reasons.
- The US pays more for new drugs than the rest of the world
- The US contribution is disproportionate, and is major driver of the drug development industry.
-If the US paid less for new drugs, the entire industry would slow, and we would have fewer more effective treatments.